13 December 2024 - The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion.

Eli Lilly announced today that the EMA CHMP has issued a positive opinion for Omvoh (mirikizumab), an interleukin-23p19 antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Read Eli Lilly press release